142,964 research outputs found
Protective Effects of L-Dopa and Carbidopa Combined Treatments on Human Catecholaminergic Cells
No full textParkinson's disease (PD) is one of the most common neurodegenerative disorders characterized by decreased levels of the neurotransmitter dopamine (DA) in the striatum of the brain, as a result of degeneration of DA neurons. Levodopa (L-Dopa) crosses the blood–brain barrier and its administration replenishes the loss of DA in dopaminergic neurons in PD patients. Despite the evident beneficial effects, L-Dopa use may cause side effects and its toxicity found in in vitro assays has been attributed to the generation of reactive oxygen species (ROS): L-Dopa is converted to DA and its metabolism and autoxidation gives rise to quinones, semiquinones, and hydrogen peroxide. Despite this evidence, L-Dopa in some in vivo and in vitro experiments showed no toxic effects, or even antioxidant effects. Two major peripheral L-Dopa metabolic pathways, driven by the enzymes Aromatic L-amino acid decarboxylase (AADC) and catechol-O-methyl transferase (COMT), significantly deplete the amount of L-Dopa reaching the brain. The low bioavailability of L-Dopa may cause a wide variation in clinical response between patients. Strategies addressing to improve the bioavailability of L-Dopa include coadministering L-Dopa with carbidopa, a decarboxylase inhibitor, as multiple daily doses. We utilized catecholaminergic human neuroblastoma cells to study DNA damage and ROS production after L-Dopa and carbidopa treatments. Our data lead us to confirm that L-Dopa may have a protective effect on dopaminergic cells especially at certain concentrations, in particular, toward the production of ROS and their toxic effects on DNA. Furthermore in the combined treatment, with induction of ROS following administration of H2O2, carbidopa is effective in reducing the damage caused by reactive oxygen intermediates both alone and in combination with L-Dopa
Erbario farmaceutico c. 1730
No full textEtichette manoscritte sul dorso: "Erbario farmaceutico c.1730" e "Dono del prof. G.B. De Toni 1902".
"Il contenuto riflette l\u27intento di documentare con criteri scientifici un insieme di vegetali aventi importanza farmacologica più che officinale in senso lato, senza trascurare tuttavia "cultivar" straordinarie, come quelle flore pleno e alcune entità il cui uso ornamentale si stava diffondendo nei giardini e negli Orti Botanici".
Da "Herbarium", a cura di Luigino Curti, Signum c1993: https://galileodiscovery.unipd.it/discovery/fulldisplay?context=L&vid=39UPD_INST:VU1&search_scope=MyInst_and_CI&tab=Everything&docid=alma99000034327020604
Tavole botaniche
No full textSecondo una nota manoscritta di Saccardo sulla carta di guardia (1913) si tratta di tavole disegnate da Morandi attorno al 1740, riprendendole da opere botaniche diverse.
19 di queste sono state poi pubblicate nel volume "Hisotria botanica practica" (vai alla scheda catalografica: https://galileodiscovery.unipd.it/discovery/fulldisplay?context=L&vid=39UPD_INST:VU1&search_scope=MyInst_and_CI&tab=Everything&docid=alma990003969250206046 ) dello stesso Morandi (che in tutto ne comprende 68) e altre 15 sono simili alle precedenti ma, sempre secondo Saccardo, non furono scelte per la pubblicazione forse perché ritenute meno importanti per quell\u27opera.
Oltre a queste, il volume comprende altre 30 tavole (di cui una dipinta), con il nome della pianta rappresentata e una descrizione più o meno dettagliata
Nerve Conduction and Ultrasound: will the wedding give birth to new morpho-functional measures?
No full textThe International Society of Peripheral Neurophysiological Imaging: pioneering innovation in a multidisciplinary context
No full textChange occurs at an increasingly fast pace in medicine. A decade ago, peripheral nerve ultrasound was a relative novelty, but a select group of clinicians saw promise in integrating anatomical information with the problems they encountered in everyday practice. Neurologists, physiatrists, rheumatologists, radiologists and others published their observations and the field expanded. A MEDLINE database search demonstrates a progressive increase in the number of nerve ultrasound publications each year, confirming growing interest
Absent median nerve P14 far-field somatosensory evoked potential with persistent tibial nerve P30 component in a patient with ischemic pontine lesion
No full textn a patient with an ischemic lesion of the right paramedian region of the pons, somatosensory evoked potential (SEP) recording to median nerve stimulation showed an absent P14 response with still preserved P13 and N18 potentials. The tibial nerve P30 and N33 SEP components were normal. Our results suggest that the median nerve P14 potential, absent in our patient, has a different origin from the tibial nerve P30 response, normal in the present case
Venezia e l\u27Adriatico.
No full textSelezione di mappe del 19. secolo di vari formati raffiguranti la città di Venezia, la sua laguna, l\u27entroterra e l\u27Alto Adriatic
Author correction to: l-acetyl-carnitine in patients with carpal tunnel syndrome: effects on nerve protection, hand function and pain
No full textBackground and Aim: L-Acetyl-carnitine (LAC) exerts an energetic effect on nerves and muscles. Recently, preclinical experiments have demonstrated a central anti-nociceptive action.
Objective: Our objective was to assess the effects of LAC on neuroprotection, pain, and function in carpal tunnel syndrome (CTS), a very frequent chronic compressive neuropathy.
Methods: In a multicentre, examiner-blinded, clinical and neurophysiological 4-month study, we enrolled 82 patients and examined 120 hands with CTS of mild to moderate severity. Patients were assessed at baseline and 10, 60 and 120 days after treatment with LAC 500 mg twice daily (BID). All patients underwent a conduction study of the median nerve, the Boston Carpal Tunnel Questionnaire (BCTQ) and the Neuropathic Pain Symptom Inventory(NPSI). The primary endpoint was the sensory conduction velocity (SCV) of the median nerve.
Results: The primary endpoint was met, with significant improvement of the SCV (P\0.0001). All sensory neurophysiological measures also significantly improved. BCTQ score changed significantly (P\0.0001), with a greater improvement in the symptom component. Nine of the NPSI types of pain, particularly squeezing and pressure pain and pain evoked by pressure, showed a significant reduction (P\0.0001).
Conclusions: Our clinical and neurophysiological study indicated that 4 months of treatment with LAC exerted a neuroprotective effect. LAC reduced pain in patients with mild and moderate CTS, a result that is possibly due to both its neuroprotective action and its central anti-nociceptive properties.
Clinical Trials Registration code: EudraCT 2014-002289-62
- …
